Omeros is a Seattle biotechnology company that develops drugs targeting the complement system, including its approved treatment YARTEMLEA. It last closed at $13.21 on Nov 20, down 5.71% on the day. The next earnings report for OMER is expected around Tue, Mar 30, 2027, after the close. For the quarter ended Sep 2026, OMER reported EPS of -$0.79 on revenue of $35.9M. Over its last 8 reports the stock moved an average of 15.1% the session after earnings. Over the last 12 months OMER insiders bought $0 of stock on the open market and sold $3.0M, according to SEC Form 4 filings.
AI Auto Pilots
Is OMER in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold OMER.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on OMERStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
OMER · as of the Nov 20 close · updated each morning
Pullback inside a longer uptrend, oversold
The stock is 28% below its 20 day and 35% below its 50 day average. It is 5% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 31), oversold. The nearest support is the Pivot S1 at $12.89, and the nearest resistance the Pivot at $13.39.
Short trendBearish
Long trendBullish
MomentumWeak
StretchOversold
VolatilityHigh, 8.1%/day
Key levels
$21.2452 week high+60.8%
$18.14Swing high (Aug 13)+37.3%
$17.8350 day average+35.0%
$16.9120 day average+28.0%
$16.04100 day average+21.4%
$13.84200 day average+4.8%
$13.70Pivot R1+3.7%
$13.39Pivot+1.4%
$13.21Last close
$12.89Pivot S1−2.4%
$12.70Swing low (Nov 17)−3.9%
$6.7052 week low−49.3%
Indicators
RSI (14)
30.51
Weak, oversold below 30
Neutral
MACD
-0.95
Below its signal line
Bearish
Stochastic
19.8
Near the bottom of its range
Oversold
ADX (14)
21.5
Weak trend
Williams %R
-91.6
Oversold below −80, overbought above −20
Oversold
CCI (20)
-190.3
Oversold below −100, overbought above 100
Oversold
Rate of change
−21.9%
Change over 10 sessions
Bearish
ATR (14)
$1.07
Typical daily range, 8.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Uptrend
Short trendBullish
Long trendBullish
MomentumWeak
StretchNormal
VolatilityNormal, 17.7%/day
Key levels
$21.2452 week high+60.8%
$18.14Swing high (Aug 13)+37.3%
$17.8350 day average+35.0%
$16.9120 day average+28.0%
$16.04100 day average+21.4%
$13.84200 day average+4.8%
$13.70Pivot R1+3.7%
$13.39Pivot+1.4%
$13.21Last close
$12.89Pivot S1−2.4%
$12.70Swing low (Nov 17)−3.9%
$6.7052 week low−49.3%
Indicators
RSI (14)
44.64
Middle of its range
Neutral
MACD
1.18
Below its signal line
Bearish
Stochastic
38.1
Middle of its range
Neutral
ADX (14)
25.2
Trending down
Williams %R
-94.0
Oversold below −80, overbought above −20
Oversold
CCI (20)
-39.0
Oversold below −100, overbought above 100
Neutral
Rate of change
−27.7%
Change over 10 sessions
Bearish
ATR (14)
$2.34
Typical daily range, 17.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Above
MA 200Above
What happened before, for OMER
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how OMER did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow OMER usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for OMERHow many large options trades hit OMER, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in OMER in the last 90 days.
From SEC Form 4 filings by OMER's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether OMER is in one of them and how their past OMER trades turned out.
Omeros is a biotechnology company based in Seattle, Washington, that develops drugs aimed at the complement system, a part of the body's immune system. Its approved product, YARTEMLEA, treats thrombotic microangiopathy, a serious complication that can follow stem cell transplants, and it is sold for use in the United States. The company is also developing treatments for other immune conditions and for addiction. Its customers are patients and the hospitals and doctors who treat them.